These two get discussed as though they are interchangeable, and they are not — different molecules, different mechanisms, different average results, and different practical trade-offs. Here is what separates them, what the trial numbers do and do not tell you about your own outcome, and the factors that usually decide it in practice.

Where we stand: Menova is an independent publication. We sell no medication and prescribe nothing. We do earn referral commissions from some care providers we compare, disclosed on our affiliate disclosure page. This is general education, not medical advice.

The mechanical difference

Semaglutide — the active ingredient in Ozempic and Rybelsus (approved for type 2 diabetes) and Wegovy (approved for weight management) — is a GLP-1 receptor agonist. It mimics one gut hormone: GLP-1, which regulates appetite, blood sugar, and how quickly the stomach empties.

Tirzepatide — the active ingredient in Mounjaro (type 2 diabetes) and Zepbound (weight management) — acts on two receptors. It mimics GLP-1 and also GIP, another incretin hormone. That dual action is thought to explain the difference in average results.

Both are weekly injections. Both are titrated upward over months rather than started at the full dose.

What the trials show

Head-to-head and comparative trial evidence has generally shown greater average weight loss with tirzepatide, with semaglutide also producing substantial average loss. Both improve glycemic control in type 2 diabetes.

Three caveats that matter more than the headline:

  • Averages are not predictions. Individual response varies enormously. Some people respond better to the drug with the lower average.
  • Trial conditions are not real life. Participants receive structured support and monitoring most people do not get.
  • Different drugs have different evidence bases beyond weight. Semaglutide has a longer record and cardiovascular outcome data in specific populations. If you have cardiovascular disease or kidney disease, that evidence may matter more to your clinician than the weight-loss difference.

Side effects: overlapping, not identical

The profiles are broadly similar — gastrointestinal effects dominate both. Nausea, vomiting, diarrhea, constipation, and reflux are common, mostly during dose escalation, and usually improve with slower titration.

Both carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies, and both are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. Both are associated with pancreatitis and gallbladder problems, and rapid weight loss itself raises gallstone risk.

Two practical points people miss: both slow gastric emptying, which matters before surgery or sedation — tell your anesthetist. And both can affect absorption of oral medications, which is relevant if you take oral contraceptives or thyroid medication.

Which one you tolerate better is genuinely individual. Switching because of side effects is a normal clinical decision, not a failure.

What actually decides it in practice

For most people, the choice comes down to factors that have nothing to do with the trial numbers:

  • Insurance coverage, which frequently determines availability outright
  • Cost, which differs by brand, dose, and pharmacy
  • Supply, which has fluctuated for both
  • Your medical history — diabetes versus weight management, cardiovascular or kidney disease, pancreatitis, gastroparesis
  • Which one you tolerate, only knowable by trying
  • Whether the program offers FDA-approved product or a compounded version — a genuine quality distinction, not a technicality

For women in midlife specifically

Two additions to the standard conversation.

Protect muscle. Perimenopause and menopause already erode lean mass, and rapid weight loss removes more. Losing muscle worsens the insulin resistance you are likely trying to address; see insulin resistance in menopause. Two resistance sessions a week and protein at every meal are not optional extras here — see strength training and eating for menopause. Ask specifically how muscle will be monitored.

Check what else is driving it. Thyroid disease, iron deficiency, and sleep apnea all produce midlife fatigue and weight change, and none is treated by these medications; see when menopause might not be the answer. And if broken sleep from night sweats is the underlying driver, treating that may do more than either drug — see GLP-1s for perimenopause weight gain.

The part about stopping

Neither is designed as a short course. Trials consistently show weight returns after stopping, often substantially. That is not a moral failure — these medications modify appetite signalling, and the signalling returns when they do.

The practical implication is that the decision to start is really a decision about the next several years: cost, monitoring, and what your maintenance plan looks like. Ask about it before you begin rather than at the point you want to stop.

Questions to bring

  • Given my history and goals, which would you choose, and why that one?
  • What does the total cost look like over twelve months, including dose escalation?
  • Is this the FDA-approved product or a compounded version?
  • What side effects mean we pause or switch?
  • How will we protect and monitor muscle mass?
  • What is the plan if I stop?

Comparing programs

The medication choice matters less than the quality of the program prescribing it. Our GLP-1 program comparison lays out clinician access, monitoring, medication source, and total cost side by side, and our guide to how to get a GLP-1 online covers the process and the red flags.

The free 2-minute Menova self-check helps you separate menopausal symptoms from metabolic ones first — no account, not a diagnosis, and your answers never leave your device.

This article is general education, not medical advice, and not a recommendation for or against either medication. Both are prescription drugs with boxed warnings and significant contraindications. Decide with a licensed clinician who knows your full history.

Sources: FDA — Semaglutide, FDA — Drug Approvals and Announcements, NIDDK — Weight Management, and ACOG.